Food editing
Some gene editing has already addressed common problems in livestock farming. For instance, horns are mostly considered a nuisance and danger in dairy cattle, leading many breeders to remove them with rather brutal procedures. Naturally hornless breeds exist and are used for beef production, but are not suitable as dairy producers. With gene editing, the genetic disposition to grow horns can be readily removed from the genome of a dairy cattle breed, solving the problem once and for all, as researchers at the start-up company Recombinetics in St. Paul, Minnesota, USA, have demonstrated. The fi rst hornless cattle produced by gene editing were born in 2015.
Improvements of edible parts of farmyard animals are also under investigation. For instance, the teams of Huping Jiao and Daxin Pang at Jilin University, Changchun, China have bred pigs with increased muscle mass by inactivating the gene for the regulatory protein myostatin (Sci. Rep. (2015) 5, 16623) . However, when genetic alterations affect the texture of the steaks, the fear of Frankenfoods is likely to raise its head again, along with concerns about animal welfare and about possible technology transfer from animal to human embryos. For these reasons, genetically edited meat products may face more of a struggle in terms of acceptance. In the UK, the Nuffi eld Council on Bioethics released a preliminary report on genome editing, concluding that the ethical implications of its use either in humans or in livestock require further scrutiny (https://goo.gl/Kxi97c).
The situation looks generally more promising in plant breeding where small edits in crop genomes could lead to dramatic improvements in effi ciency, disease resistance, and nutritional value of crops -the kind of improvements that global food production needs in order to keep up with the growth of world population and maintain food security in the second half of this century.
Among the fi rst gene-edited food products to reach consumers might be mushrooms. The group of Yinong Yang at Pennsylvania State University, USA, has developed a genetic procedure to stop common food mushrooms such as Agaricus bisporus -which is known under various names, such as button mushroom in its immature form and as Portobello in its mature stage -from turning brown on contact. The edit involves disabling one of six genes coding for the enzyme polyphenol oxidase.
This could be an interesting test case for society and consumer
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Harvest time for CRISPR-Cas?
The revolutionary gene editing technology CRISPR-Cas is on the verge of widespread application in agriculture, promising easy access to dramatic crop improvements. Companies now licensing the technology face the challenge of regaining the public trust that was lost in the GM debate. Additional insecurity comes from the ongoing patent dispute between two renowned US institutions. Michael Gross reports. developing tools for gene editing in rice, as preliminary publications and protocols document. Specifi cally, a recent report has broadened the applicability of CRISPR-Cas in rice by overcoming the requirement for an NGG motif near the target site (Mol. Plant (2016) 9, 943-945) .
Researchers at DuPont Pioneer, a genetically modifi ed organism (GMO) producer based at Johnston, Iowa, USA, have used gene editing to improve the resilience of maize and soybean plants against environmental stress. The company Cibus at San Diego, California, has developed a rapeseed variant resistant to a specifi c weedkiller -an approach reminiscent of the much-criticised Monsanto strategy of "RoundUp-Ready" GM crops enabling farmers to use the herbicide RoundUp to kill off all other vegetation. With such echoes of the past, will the new technology fare better than the previous version?
Regulation and acceptance
As more and more crop variants and livestock breeds are created by CRISPR-Cas gene editing, the big question is how regulators and consumers around the world will respond to these manipulations.
In an important precedent, the US Department of Agriculture (USDA) has told Yinong Yang in April 2016 that his anti-browning mushrooms don't require state regulation in the USA.
This was the fi rst such decision from the USDA for a variant created by CRISPR-Cas, but it follows the logic of several similar exemptions for work using the older technologies, TALEN and zinc fi nger nucleases. Essentially, the authorities believe that the controls introduced for GMOs in the 20 th century are only necessary when foreign DNA is introduced into the manipulated organism, which was inevitably the case with the old GMO biotechnology.
With the new technologies, changes can be as subtle as an exchange or removal of a single base pair. This means that the genetic alterations inherited by descendants of the targeted individual are indistinguishable from naturally occurring point mutations. Moreover, the precisely targeted nature of the change means that harmful side effects are less likely than in conventional methods used to speed up mutation rates and create a wider variety for selective breeding. In this context, mutagenic chemicals and radiation have been used, making the new technique look not only more elegant and effi cient, but also green and sustainable.
The European Union has yet to regulate on CRISPR-Cas products, but it appears plausible that it, too, may draw the line at the introduction of foreign DNA -if only because small edits are impossible to police as they look just like natural mutations.
Whether consumers, especially in Europe, will be equally understanding remains an open question, especially considering the fi erce opposition against 20 th -century style GMOs in some European countries. For producers it will be crucial to communicate to consumers that the new products will be more natural than many things they bought before, and can in some cases even support more sustainable farming and reduce cruelty to animals.
Another advantage could be in the fact that the new technology is so easy to use that any small start-up company can try its luck in the new response, but it is not going to have much effect on global food security. The big issues there are the world's staple crops including rice and wheat, and the risks they are facing from disease and climate change (Curr. Biol. fi eld, and poorer countries could also develop their own biotechnology approaches. This more democratic approach to agro-biotech could conceivably gain back some of the trust that giant companies like Monsanto and DuPont lost in the GM debate, when they were accused of trying to make farmers dependent on their seed monopoly.
In this context, it may not be entirely good news for the CRISPR technology that Monsanto has acquired a nonexclusive license for the use of the methods patented by the Broad Institute.
Sharing the credit
Seeing that the invention of targeting Cas9 at DNA unrelated to its original function is generally credited to Doudna and Charpentier based on their seminal in vitro experiments (Science (2012) 337, 816-821), it comes as a surprise that most of the patents in the fi eld have been granted to the Broad Institute, based on Zhang's work with eukaryotic cells published only half a year later.
While the University of California fi rst applied for patents on the technology, the Broad Institute applied for a fasttrack treatment and got their patents granted in April 2014, against which the University of California fi led an appeal a year later. What the patent offi ce will have to clarify is whether the later work with cells is a simple and logical application of the earlier in vitro work, or whether it constitutes an independent invention. At the time of going to press, the case is still wide open. A number of biotech start-ups that have built their business plans on licenses obtained from the Broad may have to go back to the drawing board if the institute loses its patents.
Apart from the business implications, the patent dispute may also have changed the course of Nobel Prize history. Doudna and Charpentier would have been strong candidates for the chemistry prize in 2015 or 2016, but Stockholm will now likely await a defi nitive decision on the patents before the inventors can reap their rewards.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk
Q & A Michael Engel
Michael S. Engel is an invertebrate paleontologist and entomologist whose undergraduate training was in cell biology (BS, 1993) and chemistry (BA, 1993) What drew you to your fi eld? I suppose it has been my passion for history, be it of civilizations or of phyla. I shared with many children a fascination for roaming about outdoors -in my case the hills around our home in Walnut Creek, California. But, I was not an insect or fossil collector, nor did I ever profess a desire to become a biologist or paleontologist. It was not until university that my path crossed those of numerous faculty working in systematics and taxonomy. Systematics sits at the conjoining hub of seemingly disparate disciplines, satisfying my broad appetites, while taxonomically I enjoy the hearty salmagundi offered by the arthropods, and insects in particular. If we wish to learn much about the history of terrestrial life on Earth, then who better to genufl ect to than evolution's greatest prodigies.
Who were your key early infl uences? Two, truly pivotal infl uences were Charles D. Michener and Kumar Krishna. Both were taxonomists, but were also great humanists and broadly curious evolutionary biologists. Michener's work on the systematics and natural history of bees spawned fi elds as diverse as numerical taxonomy and sociobiology, achievements that landed him in the National Academy of Sciences. Krishna was the leading authority on the biology and evolution of termites. Beyond their impressive academic accomplishments, it was the manner in which both carried themselves that most impacted me.
They imparted a value for individuals, the importance of humility, an enthusiasm for sharing knowledge, and an appreciation of history.
If not a biologist, what would you have become? As a child I was very much into the arts -classical music, illustration, craftwork -but I lacked talent for those to be anything more than hobbies. Simultaneously, I have been obsessed with ancient cultures, languages, religions, and mythology. Even today, I while away hours reading about such subjects. I therefore suppose I would have pursued a career in either history, archeology or philological decipherment. In such a parallel universe, I would wish to emulate Michael Ventris and crack something like Proto-Elamite writing, opening a once lost civilization to the world. Or, like Arthur Evans, reveal transitional periods and civilizations fundamental to characterizing the historical development of the human condition. The past is consanguineous with the present, representing an uninterrupted chain of descent, and even the false starts and dead ends inform us of ultimate answers.
What advice do you have for younger biologists? If I had to make one recommendation, I believe it would be to spend more time reading outside of one's own narrow specialization. Often when
